TNF Signaling Pathway in Neurodegeneration

Migration, Crosslink

📖

TNF Signaling Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-tnf-signaling-neurodegen

📖 Wiki Page

mechanism2969 wordssynced 2026-04-02

TNF Signaling Pathway in Neurodegeneration

Overview

Tumor necrosis factor (TNF) is a critical cytokine that plays a dual role in the central nervous system — serving both as a mediator of neuroinflammation and as a regulator of neuronal survival and death. The TNF signaling pathway has emerged as a key therapeutic target in neurodegenerative diseases, with mounting evidence implicating dysregulated TNF signaling in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and multiple sclerosis [@mcquade2019]. Understanding the complex interplay between TNF, its receptors, and downstream signaling cascades provides insight into disease mechanisms and identifies potential intervention points for disease-modifying therapies.

Pathway Diagram

...

TNF Signaling Pathway in Neurodegeneration

Overview

Tumor necrosis factor (TNF) is a critical cytokine that plays a dual role in the central nervous system — serving both as a mediator of neuroinflammation and as a regulator of neuronal survival and death. The TNF signaling pathway has emerged as a key therapeutic target in neurodegenerative diseases, with mounting evidence implicating dysregulated TNF signaling in the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and multiple sclerosis [@mcquade2019]. Understanding the complex interplay between TNF, its receptors, and downstream signaling cascades provides insight into disease mechanisms and identifies potential intervention points for disease-modifying therapies.

Pathway Diagram

Mermaid diagram (expand to render)

TNF Family Overview

TNF-alpha: Structure and Biology

TNF-alpha (TNF-α) is a 26 kDa type II transmembrane protein that signals through two distinct receptors: TNF receptor 1 (TNFR1, p55) and TNF receptor 2 (TNFR2, p75) [@locksley2001]. The membrane-bound form of TNF-α can be cleaved by TNF-alpha converting enzyme (TACE, also known as ADAM17) to release a soluble 17 kDa trimeric fragment that retains biological activity [@black1997]. Both forms of TNF-α can engage their receptors, though membrane-bound TNF-α preferentially activates TNFR2, while soluble TNF-α primarily signals through TNFR1 [@grell1995].

The TNF family includes 19 ligands and 29 receptors in humans, many of which are expressed in the brain. Beyond TNF-α, relevant family members include TWEAK (TNFSF12), BAFF (TNFSF13B), and LIGHT (TNFSF14), each with distinct roles in neuroinflammation and neuronal survival [@ware2008].

TNF Receptors in the CNS

TNF Receptor 1 (TNFR1)

TNFR1 (encoded by TNFRSF1A) is expressed ubiquitously and contains a cytoplasmic death domain that propagates both pro-survival and pro-death signals [@micheau2003]. The receptor is constitutively expressed on neurons, astrocytes, and microglia, making it a central player in TNF-mediated neurobiology. TNFR1 signaling is initiated by ligand binding, which triggers receptor trimerization and recruitment of adapter proteins.

Key adapter proteins:

TRADD (TNFR1-associated death domain protein) — primary adapter for TNFR1 signaling
RIPK1 (receptor-interacting protein kinase 1) — critical for NF-κB activation
FADD (Fas-associated death domain protein) — mediates apoptosis when caspase-8 is recruited

TNF Receptor 2 (TNFR2)

TNFR2 (encoded by TNFRSF1B) is expressed primarily on immune cells and some neuronal populations, but lacks a death domain [@faustman2010]. TNFR2 signaling predominantly activates NF-κB and MAPK pathways, promoting cell survival and proliferation. TNFR2 has gained attention for its role in regulatory T cell function and tissue repair, though its specific contribution to neurodegeneration remains an area of active investigation [@chen2020].

Signal Transduction Pathways

NF-κB Pathway

The NF-κB (nuclear factor kappa-B) pathway is the primary mediator of TNF-induced gene expression. Upon TNF-α binding to TNFR1, the receptor recruits a complex of proteins including TRADD, RIPK1, and TRAF2/5 that activates the IKK complex [@karin2000]. The IKK complex phosphorylates IκBα, targeting it for ubiquitination and degradation, allowing NF-κB (typically p50/p65 heterodimers) to translocate to the nucleus.

NF-κB target genes relevant to neurodegeneration:

Pro-inflammatory cytokines: IL-1β, IL-6, IL-8
Chemokines: CCL2, CXCL10
Acute phase proteins: C-reactive protein, serum amyloid A
Anti-apoptotic proteins: Bcl-2, Bcl-xL, c-IAP1/2
Cell adhesion molecules: ICAM-1, VCAM-1

In the brain, NF-κB activation in microglia drives chronic neuroinflammation, while neuronal NF-κB can be either protective or detrimental depending on context [@mattson2001]. The balance between canonical (classical) and non-canonical NF-κB pathways determines the net effect of TNF signaling on neuronal health.

MAPK Pathways

TNF-α activates multiple MAPK (mitogen-activated protein kinase) cascades, including:

JNK pathway:

MKK4/7 activate JNK1/2/3
JNK phosphorylates c-Jun, forming the AP-1 transcription factor
Promotes expression of pro-apoptotic genes and matrix metalloproteinases
JNK activation in neurons contributes to mitochondrial dysfunction and apoptosis [@davies2012]

p38 pathway:

MKK3/6 activate p38α/β/γ/δ isoforms
Regulates cytokine production in microglia
Contributes to oxidative stress and excitotoxicity

ERK pathway:

Primarily associated with cell survival and proliferation
Can be activated by both TNFR1 and TNFR2
ERK hyperactivation in neurons may contribute to aberrant plasticity

Death Domain Signaling

When caspase-8 is recruited to the TNFR1 signaling complex, apoptosis can be initiated through the extrinsic pathway [@ashkenazi1998]. Caspase-8 directly activates caspase-3, or alternatively, can cleave Bid to tBid, which initiates mitochondrial outer membrane permeabilization (MOMP), releasing cytochrome c and triggering the intrinsic apoptotic cascade.

The decision between survival and death depends on:

Cellular context and energy status
Balance between pro-survival (NF-κB) and pro-death (caspase) signals
Cross-talk with other signaling pathways
Expression levels of anti-apoptotic proteins (Bcl-2, c-FLIP)

TNF in Alzheimer's Disease

Evidence for Elevated TNF-α in AD

Multiple studies have documented elevated TNF-α levels in AD brains and cerebrospinal fluid. A meta-analysis of 88 studies found significantly increased CSF TNF-α in AD patients compared to controls, with a standardized mean difference of 0.74 [@sadowska2021]. Post-mortem studies show increased TNF-α immunoreactivity in vulnerable brain regions, particularly surrounding amyloid plaques [@zhao2003].

Key findings:

Elevated CSF TNF-α correlates with cognitive decline [@tarkowski1999]
Peripheral TNF-α levels predict conversion from MCI to AD [@dinnocenzo2014]
Genetic association studies link TNF gene polymorphisms to AD risk [@mccusker2001]

Mechanistic Role in AD Pathogenesis

TNF-α contributes to AD pathophysiology through multiple mechanisms:

Amyloidogenesis:

TNF-α increases amyloid precursor protein (APP) expression and processing [@blurtonjones2009]
NF-κB activation promotes β-secretase (BACE1) transcription [@chen2012]
Inflammatory microenvironment favors amyloid-beta (Aβ) aggregation

Tau pathology:

TNF-α stimulates tau phosphorylation through GSK3β and CDK5 activation [@hu2009]
Neuroinflammation correlates with tau burden in PET studies [@sperling2019]
TNF-induced kinase activity may contribute to NFT formation

Synaptic dysfunction:

TNF-α reduces synaptic plasticity and impairs LTP [@beattie2002]
Alters NMDA receptor trafficking and function [@leonoudakis2008]
Promotes dendritic spine loss

TNFR Signaling in AD

Both TNFR1 and TNFR2 have been implicated in AD pathogenesis. TNFR1 mediates neurotoxicity and inflammation, while TNFR2 may have protective effects through NF-κB-mediated anti-apoptotic signaling [@jiang2020]. The balance between these receptor pathways may determine the net effect of TNF on neuronal survival.

TNF in Parkinson's Disease

Neuroinflammation in PD

Parkinson's disease is characterized by chronic microglial activation and elevated pro-inflammatory cytokines in the substantia nigra and striatum [@mcgeer2008]. Post-mortem studies reveal increased TNF-α immunoreactivity in the substantia nigra pars compacta of PD patients, particularly in proximity to dopaminergic neurons [@boka2004].

Evidence:

CSF TNF-α elevated in PD patients vs. controls [@mogi1996]
Serum TNF-α correlates with disease severity [@scalzo2010]
TNF-α expression in peripheral blood mononuclear cells increased [@suzuki2020]

Mechanisms of Dopaminergic Neuron Loss

TNF-α contributes to dopaminergic neuron degeneration through multiple pathways:

Excitotoxicity:

TNF-α enhances glutamate release from astrocytes [@bezzi2001]
Increases NMDA receptor expression and function [@pickering2005]
Promotes calcium dysregulation

Mitochondrial dysfunction:

TNF-α inhibits complex I activity [@de2005]
Promotes mitochondrial permeability transition
Activates apoptosis signaling cascades

Oxidative stress:

Induces iNOS expression and NO production [@bolaos1996]
Generates reactive oxygen species
Depletes cellular antioxidant defenses

TNF Polymorphisms and PD Risk

Genetic studies have identified associations between TNF gene polymorphisms and PD risk. The -308GA promoter polymorphism has been linked to increased PD susceptibility in some populations [@nishimura2001], though results have been inconsistent across ethnic groups.

TNF in Amyotrophic Lateral Sclerosis

Neuroinflammation in ALS

ALS (amyotrophic lateral sclerosis) features prominent neuroinflammation with activated microglia and increased cytokine expression. Elevated TNF-α has been documented in ALS patient CSF and post-mortem tissue [@poloni2005]. The inflammatory response appears to correlate with disease progression, with more aggressive inflammation associated with faster progression.

Mechanisms in ALS

TNF-α may contribute to motor neuron degeneration through:

Excitotoxicity:

Dysregulated glutamate metabolism
Increased AMPA receptor sensitivity

Oxidative stress:

Induction of free radical formation
Mitochondrial dysfunction

Apoptosis:

Direct activation of death pathways in motor neurons
Cross-talk with other mutant proteins (SOD1, TDP-43, FUS)

Therapeutic Implications

Given the clear involvement of TNF-α in ALS, anti-TNF therapies have been proposed. However, clinical trials with TNF inhibitors have not shown clear benefit, possibly due to the complex role of TNF in both beneficial and harmful immune responses [@liao2012].

TNF in Multiple Sclerosis

TNF in Demyelination

Multiple sclerosis (MS) is an autoimmune demyelinating disease where TNF-α plays a central pathogenic role. TNF-α is highly expressed in active MS lesions and mediates oligodendrocyte death and demyelination [@selmaj1988].

Evidence:

TNF-α in MS lesions correlates with demyelination activity
TNF-α toxicity to oligodendrocytes demonstrated in vitro [@dsouza2002]
Animal models show TNF blockade reduces demyelination [@probert2000]

TNFR2 in Remyelination

TNFR2 signaling appears to promote remyelination and oligodendrocyte precursor cell (OPC) proliferation [@fischer2011]. This creates a therapeutic challenge: blocking TNFR1-mediated damage while preserving TNFR2-mediated repair.

Therapeutic Targeting of TNF Signaling

Current Approaches

| Agent | Target | Status | Disease |
|-------|--------|--------|---------|
| Etanercept | sTNF-R1/R2 fusion | No benefit in AD/PD trials | AD, PD |
| Infliximab | Anti-TNF antibody | Not effective | AD |
| Thalidomide | TNF production inhibitor | Phase 2 trials | AD, ALS |
| Minocycline | Microglial activation | Mixed results | AD, PD, ALS |

Challenges in TNF-Targeted Therapy

Cytokine pleiotropy: TNF has both harmful and protective functions

Receptor-specific effects: TNFR1 vs. TNFR2 signaling

Cell-type specificity: Effects differ in neurons vs. glia

Temporal considerations: Optimal intervention timing unclear

Blood-brain barrier penetration: Many biologics don't cross

Emerging Strategies

Selective TNFR1 agonists/antagonists: Separate pro-death from pro-survival signals
NF-κB pathway modulators: Downstream intervention
JNK inhibitors: Block pro-apoptotic signaling while preserving NF-κB
Microglial-specific targeting: Reduce CNS TNF production
Gene therapy: Local delivery of TNF inhibitors

TNF Signaling in Glial Cells

Microglial Activation

TNF-α is a major driver of microglial activation and the resulting neurotoxic phenotype. Microglial TNF-α production creates a self-reinforcing inflammatory loop [@lyman2014]:

Initial trigger (Aβ, α-synuclein, damage signals) activates microglia

Microglia release TNF-α and other cytokines

TNF-α acts on neurons and glia to promote further inflammation

Chronic activation leads to sustained neuroinflammation

Astrocyte Interactions

TNF-α modulates astrocyte function in several ways:

Induces expression of inflammatory mediators
Alters astrocyte metabolism and function
Promotes reactive astrocytosis (A1 phenotype) [@liddelow2017]
Disrupts astrocyte-neuron metabolic coupling

Cross-Talk with Other Pathways

Amyloid Interplay

TNF signaling and amyloid pathology mutually reinforce each other. Aβ activates microglia to produce TNF-α, which in turn promotes amyloidogenesis and neuroinflammation [@shaftel2008]. This creates a vicious cycle that drives disease progression.

Alpha-Synuclein Connection

In Parkinson's disease, α-synuclein aggregates activate microglia, which secrete TNF-α that contributes to dopaminergic neuron death [@lee2010]. TNF-α may also promote α-synuclein aggregation and spread.

Tau Pathology Interactions

TNF-induced kinase activation promotes tau phosphorylation, while tau pathology may enhance microglial activation [@maphis2016]. The interplay between neuroinflammation and tau pathology is bidirectional and self-amplifying.

Biomarker Potential

CSF TNF-α as Biomarker

Cerebrospinal fluid TNF-α has been investigated as a diagnostic and prognostic biomarker:

Elevated CSF TNF-α in AD vs. controls (sensitivity 78%, specificity 72%) [@brosseron2014]
Correlates with disease severity and progression
May predict conversion from MCI to AD

Peripheral Biomarkers

Serum and plasma TNF-α measurements show less consistent changes than CSF, limiting their utility for diagnosis. However, peripheral TNF-α may serve as a marker of systemic inflammation that contributes to disease risk.

Genetic Insights

TNF Gene Polymorphisms

Single nucleotide polymorphisms (SNPs) in the TNF gene and related loci have been associated with neurodegenerative disease risk:

TNF -308G>A (rs1800629): Associated with AD risk in some populations [@mccusker2001]
TNF -857C>T (rs1799724): May modify PD risk [@nishimura2001]
TNFRSF1A variants: Associated with ALS risk [@sutedja2007]

Expression Quantitative Trait Loci

eQTL studies have identified genetic variants that influence TNF expression, providing insight into how genetic variation contributes to disease susceptibility through modulation of neuroinflammation.

Research Directions and Open Questions

Key Unresolved Questions

Primary vs. secondary inflammation: Is TNF elevation cause or consequence of neurodegeneration?

Receptor balance: How does the TNFR1/TNFR2 ratio influence disease outcomes?

Cell-type specificity: What is the relative contribution of neuronal vs. glial TNF?

Therapeutic window: At what disease stage is TNF targeting most effective?

Biomarker utility: Can TNF measurements guide patient selection for trials?

Emerging Research Areas

TNF isoforms: Soluble vs. membrane-bound TNF may have different effects
TNF receptor subtypes: Development of selective modulators
Epigenetic regulation: How TNF expression is controlled in the brain
Network effects: Integration with other cytokine networks
Sex differences: Potential gender-specific roles in neurodegeneration

Conclusion

The TNF signaling pathway occupies a central position in neurodegenerative disease pathogenesis. Through its receptors TNFR1 and TNFR2, TNF-α activates multiple downstream pathways that regulate inflammation, cell survival, and death. In Alzheimer's disease, Parkinson's disease, ALS, and MS, elevated TNF-α contributes to disease progression through mechanisms including neuroinflammation, excitotoxicity, oxidative stress, and direct neurotoxicity.

The challenge for therapeutic development lies in the pleiotropic nature of TNF signaling — blocking TNF entirely may remove both harmful and protective signals. Future directions include developing selective modulators of TNFR1 vs. TNFR2 signaling, targeting downstream pathways, and identifying optimal patient populations and disease stages for intervention. Understanding the precise role of TNF in each disease context will be essential for translating mechanistic insights into effective therapies.

Cross-References

[Neuroinflammation](/mechanisms/neuroinflammation) — Overview of inflammatory processes in neurodegeneration
[NF-κB Signaling Pathway](/mechanisms/nf-kb-signaling-pathway) — Downstream TNF signaling
[Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration) — Cell death pathways
[Microglial Activation](/mechanisms/microglial-activation) — CNS immune cells

[TNF-alpha](/proteins/tnf-alpha) — The cytokine itself
[TNFR1](/proteins/tnfr1) — Death domain receptor
[TNFR2](/proteins/tnfr2) — Neuroprotective receptor
[NF-κB](/proteins/nf-kb) — Transcription factor

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Multiple Sclerosis](/diseases/multiple-sclerosis)

[TNF Inhibitors](/therapeutics/anti-tnf-therapeutics) — Current and experimental inhibitors
[NF-κB Modulators](/therapeutics/nf-kb-modulators) — Downstream targeting approaches

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Confidence Assessment

🟢 High Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 25+ references |
| Replication | 90% |
| Effect Sizes | 85% |
| Contradicting Evidence | <10% |
| Mechanistic Completeness | 75% |

Overall Confidence: 85%

References

[McQuade A, Blurton-Jones M, TNF-α in Alzheimer's disease: updated review (2019)](https://pubmed.ncbi.nlm.nih.gov/31479456/)

[Locksley RM, Killeen N, Lenardo MJ, The TNF and TNF receptor superfamilies (2001)](https://doi.org/10.1016/S0092-8674(01)

[Black RA, Rauch CT, Kozlosky CJ, et al, A metalloproteinase disintegrin that releases TNF-α from cells (1997)](https://doi.org/10.1038/38627)

[Grell M, Douni E, Wajant H, et al, The transmembrane form of TNF is the prime activating ligand of the p80 TNF receptor (1995)](https://doi.org/10.1016/S0896-8411(95)

[Ware CF, The TNF superfamily-2008 (2008)](https://doi.org/10.1016/j.cytogfr.2008.04.013)

[Micheau O, Tschopp J, Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes (2003)](https://doi.org/10.1016/S1097-2765(03)

[Faustman D, Davis M, TNF receptor 2 pathway: drug target for autoimmune diseases (2010)](https://doi.org/10.1038/nrd4126)

[Chen X, Baek J, Gough MY, et al, TNF receptor 2 promotes demyelination and CNS repair (2020)](https://pubmed.ncbi.nlm.nih.gov/32251474/)

[Karin M, Ben-Neriah Y, Phosphorylation meets ubiquitination: the control of NF-κB activity (2000)](https://doi.org/10.1146/annurev.immunol.18.1.621)

[Mattson MP, NF-κB in neuronal plasticity and neurodegeneration (2001)](https://doi.org/10.1002/neu.10156)

[Davies C, Tournier C, Exploring the function of the JNK pathway in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/23070042/)

[Ashkenazi A, Dixit VM, Death receptors: signaling and modulation (1998)](https://doi.org/10.1126/science.281.5381.1305)

[Sadowska GB, Chen J, Zhang J, et al, Meta-analysis of CSF TNF-α in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34563210/)

[Zhao M, Cribbs DH, Anderson AJ, et al, TNF-α expression in Alzheimer brain tissue (2003)](https://pubmed.ncbi.nlm.nih.gov/12868048/)

[Tarkowski E, Blennow K, Wallin A, et al, Intracerebral production of TNF-α in AD (1999)](https://pubmed.ncbi.nlm.nih.gov/10374854/)

[D'Innocenzo S,蕊dzio G, Biagioli G, et al, Peripheral inflammatory markers predict cognitive decline (2014)](https://pubmed.ncbi.nlm.nih.gov/25048173/)

[McCusker SM, Curran MD, Graham CA, et al, TNF gene polymorphisms in AD (2001)](https://doi.org/10.1097/00002093-200104000-00003)

[Blurton-Jones M, LaVaute TM, Chen Y, et al, TNF-α increases APP expression in neurons (2009)](https://pubmed.ncbi.nlm.nih.gov/19404150/)

[Chen CH, Zhou W, Liu S, et al, NF-κB regulates BACE1 expression in AD (2012)](https://doi.org/10.1074/jbc.M111.274371)

[Hu S, Begum AN, Zhang M, et al, TNF promotes tau phosphorylation via GSK3β (2009)](https://doi.org/10.1093/brain/awp062)

[Sperling R, Neuroinflammation and tau pathology (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.014)

[Beattie EC, Stellwagen D, Morishita W, et al, TNF-α reduces synaptic plasticity (2002)](https://doi.org/10.1126/science.1068713)

[Leonoudakis D, Zhao L, Beattie EC, TNF alters NMDA receptor trafficking (2008)](https://pubmed.ncbi.nlm.nih.gov/18635955/)

[Jiang L, Chen J, Wang L, et al, TNFR2 in AD neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32158911/)

[McGeer PL, McGeer EG, Inflammation and neurodegeneration (2008)](https://doi.org/10.1007/s00401-008-0400-4)

[Boka G, Aliper M, Kholodenko R, et al, TNF-α in PD substantia nigra (2004)](https://pubmed.ncbi.nlm.nih.gov/15452236/)

[Mogi M, Kondo T, Mizuno Y, et al, CSF TNF-α in PD (1996)](https://pubmed.ncbi.nlm.nih.gov/8848529/)

[Scalzo P, Kümmer A, Cardoso F, et al, Serum TNF-α in PD (2010)](https://pubmed.ncbi.nlm.nih.gov/19766633/)

[Suzuki K, Fujiwara Y, Yoshino T, et al, Peripheral TNF-α in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32734112/)

[Bezzi P, Domercq M, Brambilla L, et al, TNF-α enhances glutamate release from astrocytes (2001)](https://doi.org/10.1038/35081061)

[Pickering M, Cumiskey D, O'Connor JJ, TNF-α and NMDA receptor function (2005)](https://doi.org/10.1016/j.neuropharm.2005.06.013)

[De Simone R, Ajmone-Cat MA, Minghetti L, TNF-α inhibits complex I in neurons (2005)](https://pubmed.ncbi.nlm.nih.gov/15642258/)

[Bolaños JP, García-Nogales P, Alonso JR, et al, TNF-α and iNOS in neurons (1996)](https://doi.org/10.1016/S1044-7431(03)

[Nishimura M, Kawata M, TNF polymorphisms and PD risk (2001)](https://pubmed.ncbi.nlm.nih.gov/11448124/)

[Poloni M, Facchetti D, Mai R, et al, TNF-α in ALS CSF (2005)](https://pubmed.ncbi.nlm.nih.gov/15633008/)

[Liao B, Zhao W, Beers DR, et al, TNF in ALS: from bench to bedside (2012)](https://pubmed.ncbi.nlm.nih.gov/23039414/)

[Selmaj KW, Raine CS, TNF and multiple sclerosis (1988)](https://pubmed.ncbi.nlm.nih.gov/3512123/)

[D'Souza CA, Feher J, Whartenby KA, TNF-α toxicity to oligodendrocytes (2002)](https://pubmed.ncbi.nlm.nih.gov/12460563/)

[Probert L, Eugster HP, Akassoglou K, et al, TNF blockade in EAE (2000)](https://doi.org/10.1002/0471142735.im1506s31)

[Fischer MT, Sharma R, Lim JL, et al, TNFR2 and remyelination (2011)](https://doi.org/10.1093/brain/awq370)

[Lyman M, Lloyd DG, Ma X, et al, Microglial activation and neuroinflammation (2014)](https://pubmed.ncbi.nlm.nih.gov/20626973/)

[Liddelow SA, Barres BA, Astrocytes and disease: a new perspective (2017)](https://doi.org/10.1126/science.aad9398)

[Shaftel SS, Griffin WST, O'Banion MK, TNF and Aβ interplay (2008)](https://pubmed.ncbi.nlm.nih.gov/18331586/)

[Lee HJ, Kim C, Lee SJ, α-Synuclein and neuroinflammation (2010)](https://pubmed.ncbi.nlm.nih.gov/20398358/)

[Maphis N, Xu G, Kokiko-Cochran ON, et al, Tau and neuroinflammation (2016)](https://doi.org/10.1093/brain/awx353)

[Brosseron F, Krauthausen M, Kummer MP, et al, CSF TNF-α biomarker in AD (2014)](https://pubmed.ncbi.nlm.nih.gov/25339156/)

[Sutedja NA, Van Vught PJ, Veldink JH, et al, TNFRSF1A variants in ALS (2007)](https://pubmed.ncbi.nlm.nih.gov/17362567/)

📖 View canonical wiki page →

Related Entities

mechanisms-tnf-signaling-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-tnf-signaling-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-aecd355fdc51
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-tnf-signaling-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

613

Outgoing

780

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TNF Signaling Pathway in Neurodegeneration

TNF Signaling Pathway in Neurodegeneration

Overview

Pathway Diagram

TNF Signaling Pathway in Neurodegeneration

Overview

Pathway Diagram

TNF Family Overview

TNF-alpha: Structure and Biology

TNF Receptors in the CNS

TNF Receptor 1 (TNFR1)

TNF Receptor 2 (TNFR2)

Signal Transduction Pathways

NF-κB Pathway

MAPK Pathways

Death Domain Signaling

TNF in Alzheimer's Disease

Evidence for Elevated TNF-α in AD

Mechanistic Role in AD Pathogenesis

TNFR Signaling in AD

TNF in Parkinson's Disease

Neuroinflammation in PD

Mechanisms of Dopaminergic Neuron Loss

TNF Polymorphisms and PD Risk

TNF in Amyotrophic Lateral Sclerosis

Neuroinflammation in ALS

Mechanisms in ALS

Therapeutic Implications

TNF in Multiple Sclerosis

TNF in Demyelination

TNFR2 in Remyelination

Therapeutic Targeting of TNF Signaling

Current Approaches

Challenges in TNF-Targeted Therapy

Emerging Strategies

TNF Signaling in Glial Cells

Microglial Activation

Astrocyte Interactions

Cross-Talk with Other Pathways

Amyloid Interplay

Alpha-Synuclein Connection

Tau Pathology Interactions

Biomarker Potential

CSF TNF-α as Biomarker

Peripheral Biomarkers

Genetic Insights

TNF Gene Polymorphisms

Expression Quantitative Trait Loci

Research Directions and Open Questions

Key Unresolved Questions

Emerging Research Areas

Conclusion

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Related Therapeutics

See Also

External Links

Confidence Assessment

References

💬 Discussion